Alkermes plc Stock
Price
Target price
?
?
0.000%
-
0.000%
€38.74
08:55 / Stuttgart Stock Exchange
WKN: A1JKVH / Symbol: ALKS / Name: Alkermes / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Alkermes plc Stock
There is no change in the price for Alkermes plc today.
Alkermes plc is currently one of the favorites of our community with 15 Buy predictions and no Sell predictions.
As a result the target price of 38 € shows a positive potential of 37.68% compared to the current price of 27.6 € for Alkermes plc.
Pros and Cons of Alkermes plc in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alkermes plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alkermes plc | 0.000% | -1.418% | 2.206% | -20.571% | 17.797% | 4.807% | 72.671% |
| Icon plc | 1.280% | -38.527% | -52.619% | -58.327% | -51.778% | -65.084% | - |
| United Therapeutics | 1.460% | 2.389% | 1.622% | 14.898% | -4.704% | 70.163% | 182.778% |
| Iovance Biotherapeutics Inc. | 1.470% | 1.142% | 9.086% | -59.088% | -6.619% | -67.749% | -94.387% |
Comments
Alkermes (NASDAQ:ALKS) had its price target raised by analysts at Truist Financial Corporation from $50.00 to $55.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes (NASDAQ:ALKS) had its price target lowered by analysts at Wells Fargo & Company from $42.00 to $37.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes (NASDAQ:ALKS) had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $55.00 to $45.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
